back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2025-06-12 16:41 Tx date 2025-06-11 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Starr, Christopher
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$154,000
+200,000 vol $0.77 each |
300,000 | |
| Filed 2025-06-12 16:26 Tx date 2025-06-11 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$154,000
+200,000 vol $0.77 each |
950,000 | |
| Filed 2025-06-12 16:24 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares Grant Stock Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2025-06-12 16:16 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$262,500
+750,000 vol $0.35 each |
750,000 | |
| Filed 2025-06-12 16:10 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2025-06-12 13:40 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares Grant Stock Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2025-06-12 13:40 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares Grant Stock Options
00 - Opening Balance-Initial SEDI Report
|
200,000 | ||
| Filed 2022-04-06 11:15 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-10-07 20:10 Tx date 2019-05-27 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Riggins, Brook
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Unit
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-10-07 20:06 Tx date 2024-09-26 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Riggins, Brook
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSU
56 - Grant of rights
|
+1,000,000 vol |
1,000,000 | |
| Filed 2024-10-07 18:07 Tx date 2019-05-27 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Riggins, Brook
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSU
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-10-07 15:38 Tx date 2019-05-27 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Riggins, Brook
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Unit
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-10-07 15:38 Tx date 2019-05-27 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Riggins, Brook
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Unit
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-05-20 15:40 Tx date 2024-02-05 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$164.00
+200 vol $0.82 each |
6,770,069 | |
| Filed 2024-05-20 15:39 Tx date 2024-02-05 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$13,120
+16,000 vol $0.82 each |
6,769,869 | |
| Filed 2024-05-20 15:38 Tx date 2023-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,240
+4,000 vol $0.56 each |
6,753,869 | |
| Filed 2024-05-20 15:37 Tx date 2023-03-29 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$6,360
+12,000 vol $0.53 each |
6,749,869 | |
| Filed 2023-12-18 13:50 Tx date 2023-12-15 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Riggins, Brook
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$37,500
+50,000 vol $0.75 each |
1,050,000 | |
| Filed 2023-08-03 12:58 Tx date 2023-06-02 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-375.00
-500 vol $0.75 each |
1,599,500 | |
| Filed 2023-08-03 12:56 Tx date 2023-06-05 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,129.95
-1,500 vol $0.75 each |
1,598,000 | |
| Filed 2023-08-03 12:47 Tx date 2023-07-24 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-6,080
-9,500 vol $0.64 each |
1,476,000 | |
| Filed 2023-08-03 12:43 Tx date 2023-07-21 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-13,000
-20,000 vol $0.65 each |
1,485,500 | |
| Filed 2023-08-03 12:42 Tx date 2023-07-21 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-990.00
-1,500 vol $0.66 each |
1,505,500 | |
| Filed 2023-08-03 12:40 Tx date 2023-07-18 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-6,600
-10,000 vol $0.66 each |
1,507,000 | |
| Filed 2023-08-03 12:38 Tx date 2023-07-13 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-8,320
-13,000 vol $0.64 each |
1,517,000 | |
| Filed 2023-08-03 12:36 Tx date 2023-07-10 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-6,400
-10,000 vol $0.64 each |
1,530,000 | |
| Filed 2023-08-03 12:34 Tx date 2023-07-07 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-4,875
-7,500 vol $0.65 each |
1,540,000 | |
| Filed 2023-08-03 12:33 Tx date 2023-07-07 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,320
-2,000 vol $0.66 each |
1,547,500 | |
| Filed 2023-08-03 12:30 Tx date 2023-06-29 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-700.00
-1,000 vol $0.70 each |
1,549,500 | |
| Filed 2023-08-03 12:28 Tx date 2023-06-28 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,800
-4,000 vol $0.70 each |
1,550,500 | |
| Filed 2023-08-03 12:26 Tx date 2023-06-26 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,160
-3,000 vol $0.72 each |
1,554,500 | |
| Filed 2023-08-03 12:24 Tx date 2023-06-23 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-7,770
-10,500 vol $0.74 each |
1,557,500 | |
| Filed 2023-08-03 12:21 Tx date 2023-06-20 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-740.00
-1,000 vol $0.74 each |
1,568,000 | |
| Filed 2023-08-03 12:19 Tx date 2023-06-19 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,500
-2,000 vol $0.75 each |
1,569,000 | |
| Filed 2023-08-03 12:18 Tx date 2023-06-15 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-3,700
-5,000 vol $0.74 each |
1,571,000 | |
| Filed 2023-08-03 12:15 Tx date 2023-06-14 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,500
-2,000 vol $0.75 each |
1,586,000 | |
| Filed 2023-08-03 12:12 Tx date 2023-06-15 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-390.00
-500 vol $0.78 each |
1,576,000 | |
| Filed 2023-08-03 12:11 Tx date 2023-06-15 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-3,800
-5,000 vol $0.76 each |
1,576,500 | |
| Filed 2023-08-03 12:09 Tx date 2023-06-15 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-3,465
-4,500 vol $0.77 each |
1,581,500 | |
| Filed 2023-08-03 12:00 Tx date 2023-06-12 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,500
-2,000 vol $0.75 each |
1,594,500 | |
| Filed 2023-08-03 11:58 Tx date 2023-06-09 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-365.00
-500 vol $0.73 each |
1,596,500 | |
| Filed 2023-08-03 11:56 Tx date 2023-06-13 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-4,810
-6,500 vol $0.74 each |
1,590,000 | |
| Filed 2023-08-03 11:52 Tx date 2023-06-09 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-740.00
-1,000 vol $0.74 each |
1,597,000 | |
| Filed 2023-08-03 11:49 Tx date 2023-06-05 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,129.95
-1,500 vol $0.75 each |
||
| Filed 2023-08-03 11:49 Tx date 2023-06-05 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,129.95
-1,500 vol $0.75 each |
1,598,500 | |
| Filed 2023-08-03 11:45 Tx date 2023-06-06 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-375.00
-500 vol $0.75 each |
||
| Filed 2023-08-03 11:45 Tx date 2023-06-06 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-375.00
-500 vol $0.75 each |
1,598,000 | |
| Filed 2023-08-03 11:37 Tx date 2016-02-22 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Vincent P.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
1,600,000 | ||
| Filed 2022-12-09 14:33 Tx date 2022-12-08 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Tsuchimoto, Kim R
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
100,000 | |
| Filed 2022-12-09 14:27 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Tsuchimoto, Kim R
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-12-09 09:52 Tx date 2022-12-08 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Riggins, Brook
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+150,000 vol |
900,000 | |
| Filed 2022-12-09 09:33 Tx date 2022-12-08 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Starr, Christopher
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
100,000 | |
| Filed 2022-12-09 09:17 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Starr, Christopher
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-08-02 11:39 Tx date 2022-08-02 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Riggins, Brook
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$11,000
+25,000 vol $0.44 each |
1,000,000 | |
| Filed 2022-04-11 15:54 Tx date 2022-04-05 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Stanton, Jr., Vincent Paul
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
4,000,000 | ||
| Filed 2022-04-07 21:17 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Mullally, William Hogan
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$157,500
+450,000 vol $0.35 each |
450,000 | |
| Filed 2022-04-07 13:04 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Starr, Christopher
4 - Director of Issuer
Direct Ownership
|
Options Private Third Party Options
50 - Grant of options
|
$489,999
+1,400,000 vol $0.35 each |
1,400,000 | |
| Filed 2022-04-07 13:00 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Starr, Christopher
4 - Director of Issuer
Direct Ownership
|
Options Private Third Party Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-04-06 12:15 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Riggins, Brook
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$262,500
+750,000 vol $0.35 each |
750,000 | |
| Filed 2022-04-06 11:15 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
750,000 | ||
| Filed 2022-04-06 11:06 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
6,737,869 | ||
| Filed 2022-04-05 18:50 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Tsuchimoto, Kim R
4 - Director of Issuer
Direct Ownership
|
Options Private Third Party Options
50 - Grant of options
|
+600,000 vol |
600,000 | |
| Filed 2022-04-05 18:41 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Tsuchimoto, Kim R
4 - Director of Issuer
Direct Ownership
|
Options Private Third Party Options
00 - Opening Balance-Initial SEDI Report
|